Stories highlighting important therapy and disease areas.
- BPH – a market due for enlargement as the population ages?
As the number of older men increases, so does the problem of benign prostatic hypertrophy, the cause of frequent – but often unsuccessful – trips to the bathroom.
Nov 2, 2005
- Restless legs syndrome – lifecycle benefits for dopamine agonists?
Some Parkinson’s disease therapies could see a prolonged lifespan thanks to the new neurological condition restless legs syndrome.
Oct 12, 2005
- Neurodegenerative disease: a major market in the making
A new report from IMS looks at the market for Alzheimer’s and Parkinson’s diseases drug treatments and the potential in this area as the global population ages.
Oct 12, 2005
- No more sleepless nights for Sepracor?
Sales of Lunesta, the first sleeping pill that can be taken long term, have got off to a flying start – but new competitors are nigh.
Jul 29, 2005
- Renal Cancer – Therapeutic Approaches
IMS reports on the developments in the treatment of the kidney cancer reported at the 41st ASCO meeting in Orlando.
Jun 23, 2005
- Osteoporosis – New Options for Bone Loss
IMS reviews the new products set to challenge Fosamax in the growing osteoporosis market.
May 23, 2005
- Fighting Cancer: 'Magic Bullets' on Target to Lead Market
IMS looks at the next generation of monoclonal antibody (MAb) therapeutics in development for a variety of cancers hoping to build on the success of current treatments such as Avastin and Rituxan.
Jan 28, 2005
- The Growing Authority of Patient Data
A powerful, diverse and increasingly influential decision-making tool - that was the key takeaway on longitudinal patient data from the third IMS Disease Analyzer - Mediplus forum held in London in November 2004.
Dec 16, 2004
- New Drugs Balance Genericisation of Epilepsy Market
IMS looks at the epilepsy market as Pfizer prepares for the launch of second-generation anticonvulsant Lyrica (pregabalin) in the face of generic competition for Neurontin (gabapentin).
Dec 14, 2004
- Could Cymbalta Bring Cheer for Lilly?
After a series of delays caused by problems at its manufacturing plant Lilly's new SNRI antidepressant Cymbalta finally received FDA approval in August 2004 - IMS looks at the market.
Aug 18, 2004
